Viking Therapeutics Shares Rally After Move to Advance Oral Obesity Pill into Late-Stage Trials
Viking Therapeutics saw its stock jump 11.63% following an announcement that its investigational oral obesity drug VK2735 will advance into late-stage trials in the third quarter of this year. The company cited late-stage study results showing once-daily oral dosing produced up to 12.2% average weight loss after 13 weeks and emphasized that offerin…